Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.36 |
| ▸ | MMP9 | P14780 | 9/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | FGF2 | P09038 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6546698 | 1.00 | MMP2 (0.36) | MMP2MMP9POLBALDH1A1HTT | |
| SCHEMBL7461692 | 0.91 | SMN1; SMN2 (0.35) | MMP2MMP9POLBALDH1A1HTT | |
| SCHEMBL7461694 | 0.91 | SMN1; SMN2 (0.35) | MMP2MMP9POLBALDH1A1HTT | |
| SCHEMBL7608470 | 0.76 | MMP2 (0.40) | MMP2MMP9KMT2A | |
| SCHEMBL3938395 | 0.74 | CYP1A2 (0.47) | POLBALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL9568719 | 0.72 | TSHR (0.37) | ALDH1A1SMN1; SMN2MEN1KMT2APKM | |
| SCHEMBL6546386 | 0.72 | TET2 (0.40) | POLBALDH1A1HTTSMN1; SMN2FGF2 | |
| SCHEMBL6546396 | 0.72 | TET2 (0.40) | POLBALDH1A1HTTSMN1; SMN2FGF2 | |
| SCHEMBL6547554 | 0.70 | POLB (0.39) | POLBALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL6547560 | 0.70 | POLB (0.39) | POLBALDH1A1HTTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818622-B2 | ADMINISTERING OVER A PERIOD OF AT LEAST THREE MONTHS A MATRIX METALLOPROTEINASE INHIBITOR FOR TREATMENT OF A PATIENT HAVING CANCER OR INFLAMMATION | DARWIN DISCOVERY LTD. (GB) | 2004-11-16 | — | — | US | disclosed |
| EP-0981366-B1 | SELECTIVE MMP INHIBITORS HAVING REDUCED SIDE-EFFECTS | DARWIN DISCOVERY LTD (GB) | 2004-01-21 | — | — | EP | disclosed |
| US-20020035065-A1 | Selective MMP inhibitors having reduced side-effects | BIRD JOHN (GB) | 2002-03-21 | — | — | US | disclosed |
| US-6180611-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR | DARWIN DISCOVERY, LTD. (GB) | 2001-01-30 | — | — | US | disclosed |
| EP-0784629-B1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | DARWIN DISCOVERY LTD (GB) | 1999-04-28 | — | — | EP | disclosed |
| EP-0784629-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | Chiroscience Limited (GB) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996011209-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |